Equities

Taiko Pharmaceutical Co Ltd

4574:TYO

Taiko Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)373.00
  • Today's Change7.00 / 1.91%
  • Shares traded88.60k
  • 1 Year change+15.84%
  • Beta0.5931
Data delayed at least 20 minutes, as of Nov 13 2024 04:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Taiko Pharmaceutical Co Ltd grew revenues 21.43% from 5.04bn to 6.12bn while net income improved from a loss of 4.89bn to a smaller loss of 3.61bn.
Gross margin55.73%
Net profit margin-37.15%
Operating margin-38.98%
Return on assets-16.12%
Return on equity-26.20%
Return on investment-19.68%
More ▼

Cash flow in JPYView more

In 2023, Taiko Pharmaceutical Co Ltd increased its cash reserves by 87.49%, or 2.45bn. Cash Flow from Financing totalled 1.54bn or 25.15% of revenues. In addition the company used 307.00m for operations while cash from investing totalled 1.17bn.
Cash flow per share-39.26
Price/Cash flow per share--
Book value per share160.66
Tangible book value per share160.18
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items increased 32.08%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
9.09
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.